Annual report pursuant to Section 13 and 15(d)

Financial Instruments - Additional Information (Detail)

v3.22.4
Financial Instruments - Additional Information (Detail) - USD ($)
1 Months Ended 12 Months Ended
Sep. 30, 2022
Apr. 30, 2020
Apr. 30, 2018
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Nov. 16, 2021
Schedule Of Available For Sale Securities [Line Items]              
Sale price of common stock             $ 27.74
Impairment       $ 0      
Performance Warrant [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Warrants to purchase common stock   400,000          
Warrant exercise price   $ 3.01          
Warrant exercisable   133,333          
Warrant exercisable date   Dec. 31, 2023          
Fair value of warrants           $ 43,000  
Performance Warrant [Member] | First Installment [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Warrant exercisable   133,333          
April 2018 Warrant [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Warrants to purchase common stock     20,000        
Warrant exercise price     $ 11.73 $ 11.73 $ 11.73    
Warrant exercisable date     Apr. 06, 2023        
Warrants maturity period     5 years 5 years 5 years    
Fair value of warrants     $ 207,000        
Other Noncurrent Assets [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Strategic investment       $ 2,750,000      
Stock Consideration [Member] | PandoLogic Merger Agreement [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Sale price of common stock $ 20.53            
Minimum [Member]              
Schedule Of Available For Sale Securities [Line Items]              
Contingent earnout $ 10,825,000